309 related articles for article (PubMed ID: 20564061)
1. Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy?
Culp SH; Tannir NM; Abel EJ; Margulis V; Tamboli P; Matin SF; Wood CG
Cancer; 2010 Jul; 116(14):3378-88. PubMed ID: 20564061
[TBL] [Abstract][Full Text] [Related]
2. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Heng DY; Wells JC; Rini BI; Beuselinck B; Lee JL; Knox JJ; Bjarnason GA; Pal SK; Kollmannsberger CK; Yuasa T; Srinivas S; Donskov F; Bamias A; Wood LA; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Kim JJ; Choueiri TK
Eur Urol; 2014 Oct; 66(4):704-10. PubMed ID: 24931622
[TBL] [Abstract][Full Text] [Related]
3. Nephrectomy improves overall survival in patients with metastatic renal cell carcinoma in cases of favorable MSKCC or ECOG prognostic features.
Mathieu R; Pignot G; Ingles A; Crepel M; Bigot P; Bernhard JC; Joly F; Guy L; Ravaud A; Azzouzi AR; Gravis G; Chevreau C; Zini L; Lang H; Pfister C; Lechevallier E; Fais PO; Berger J; Vayleux B; Roupret M; Audenet F; Descazeaud A; Rigaud J; Machiels JP; Staehler M; Salomon L; Ferriere JM; Kleinclauss F; Bensalah K; Patard JJ
Urol Oncol; 2015 Aug; 33(8):339.e9-15. PubMed ID: 26087971
[TBL] [Abstract][Full Text] [Related]
4. Optimizing patient selection for cytoreductive nephrectomy based on outcomes in the contemporary era of systemic therapy.
McIntosh AG; Umbreit EC; Holland LC; Gu C; Tannir NM; Matin SF; Karam JA; Culp SH; Wood CG
Cancer; 2020 Sep; 126(17):3950-3960. PubMed ID: 32515845
[TBL] [Abstract][Full Text] [Related]
5. Sarcopenia as a predictor of overall survival after cytoreductive nephrectomy for metastatic renal cell carcinoma.
Sharma P; Zargar-Shoshtari K; Caracciolo JT; Fishman M; Poch MA; Pow-Sang J; Sexton WJ; Spiess PE
Urol Oncol; 2015 Aug; 33(8):339.e17-23. PubMed ID: 26094169
[TBL] [Abstract][Full Text] [Related]
6. The independent oncological role for cytoreductive nephrectomy in metastatic renal cell carcinoma: Prognostic features in the era of targeted therapies.
Claeys T; Lumen N; Kumps C; Praet M; De Meerleer G; Rottey S; Ost P; Devisschere P; Villeirs G; Fonteyne V; Decaestecker K
Urol Oncol; 2017 Apr; 35(4):152.e13-152.e22. PubMed ID: 28153420
[TBL] [Abstract][Full Text] [Related]
7. Impact of Cytoreductive Nephrectomy on Survival in Patients with Metastatic Renal Cell Carcinoma Treated by Targeted Therapy.
Song Y; Du CX; Zhang W; Sun YK; Yang L; Cui CX; Chi YB; Shou JZ; Zhou AP; Li CL; Ma JH; Wang JW; Sun Y
Chin Med J (Engl); 2016 Mar; 129(5):530-5. PubMed ID: 26904986
[TBL] [Abstract][Full Text] [Related]
8. Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma.
Bhindi B; Abel EJ; Albiges L; Bensalah K; Boorjian SA; Daneshmand S; Karam JA; Mason RJ; Powles T; Bex A
Eur Urol; 2019 Jan; 75(1):111-128. PubMed ID: 30467042
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of the Glasgow Prognostic Score for patients with metastatic renal cell carcinoma treated by cytoreductive nephrectomy.
Fukuda H; Takagi T; Kondo T; Yoshida K; Shimizu S; Nagashima Y; Tanabe K
Int J Clin Oncol; 2018 Jun; 23(3):539-546. PubMed ID: 29302841
[TBL] [Abstract][Full Text] [Related]
10. Population-based analysis of factors associated with survival in patients undergoing cytoreductive nephrectomy in the targeted therapy era.
Culp SH; Karam JA; Wood CG
Urol Oncol; 2014 Jul; 32(5):561-8. PubMed ID: 24709415
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma treated with first-line sunitinib: a European multiinstitutional study.
Bamias A; Tzannis K; Papatsoris A; Oudard S; Beuselinck B; Escudier B; Liontos M; Elaidi TR; Chrisofos M; Stravodimos K; Anastasiou I; Mitropoulos D; Deliveliotis C; Constantinides C; Dimopoulos MA; Bamia C
Clin Genitourin Cancer; 2014 Oct; 12(5):373-83. PubMed ID: 24819319
[TBL] [Abstract][Full Text] [Related]
12. Benefit from cytoreductive nephrectomy and the prognostic role of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma.
Day D; Kanjanapan Y; Kwan E; Yip D; Lawrentschuk N; Davis ID; Azad AA; Wong S; Rosenthal M; Gibbs P; Tran B
Intern Med J; 2016 Nov; 46(11):1291-1297. PubMed ID: 27507629
[TBL] [Abstract][Full Text] [Related]
13. Prognostic effect of cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma: a comparative study using inverse probability of treatment weighting.
Klatte T; Fife K; Welsh SJ; Sachdeva M; Armitage JN; 'Aho T; Riddick AC; Matakidou A; Eisen T; Stewart GD
World J Urol; 2018 Mar; 36(3):417-425. PubMed ID: 29256020
[TBL] [Abstract][Full Text] [Related]
14. Oncologic Outcomes of Cytoreductive Nephrectomy in Synchronous Metastatic Renal-Cell Carcinoma: A Single-Center Experience.
Choi CI; Kang M; Sung HH; Jeon HG; Jeong BC; Jeon SS; Lee HM; Seo SIL
Clin Genitourin Cancer; 2018 Dec; 16(6):e1189-e1199. PubMed ID: 30262447
[TBL] [Abstract][Full Text] [Related]
15. Analysis of pre-operative variables for identifying patients who might benefit from upfront cytoreductive nephrectomy for metastatic renal cell carcinoma in the targeted therapy era.
You D; Jeong IG; Song C; Lee JL; Hong B; Hong JH; Ahn H; Kim CS
Jpn J Clin Oncol; 2015 Jan; 45(1):96-102. PubMed ID: 25341544
[TBL] [Abstract][Full Text] [Related]
16. Validation of preoperative variables and stratification of patients to help predict benefit of cytoreductive nephrectomy in the targeted therapy ERA.
Manley BJ; Kim EH; Vetter JM; Potretzke AM; Strope SA
Int Braz J Urol; 2017; 43(3):432-439. PubMed ID: 28128914
[TBL] [Abstract][Full Text] [Related]
17. Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma.
Bhindi B; Graham J; Wells JC; Bakouny Z; Donskov F; Fraccon A; Pasini F; Lee JL; Basappa NS; Hansen A; Kollmannsberger CK; Kanesvaran R; Yuasa T; Ernst DS; Srinivas S; Rini BI; Bowman I; Pal SK; Choueiri TK; Heng DYC
Eur Urol; 2020 Oct; 78(4):615-623. PubMed ID: 32362493
[TBL] [Abstract][Full Text] [Related]
18. Development of accurate models for individualized prediction of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma.
Margulis V; Shariat SF; Rapoport Y; Rink M; Sjoberg DD; Tannir NM; Abel EJ; Culp SH; Tamboli P; Wood CG
Eur Urol; 2013 May; 63(5):947-52. PubMed ID: 23273681
[TBL] [Abstract][Full Text] [Related]
19. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma.
Vasselli JR; Yang JC; Linehan WM; White DE; Rosenberg SA; Walther MM
J Urol; 2001 Jul; 166(1):68-72. PubMed ID: 11435825
[TBL] [Abstract][Full Text] [Related]
20. Overall survival in patients with metastatic renal cell carcinoma and clinical N1 disease undergoing cytoreductive nephrectomy and lymph node dissection.
Faiena I; Salmasi A; Lenis AT; Donin NM; Johnson DC; Bachour K; Drakaki A; Belldegrun AS; Pantuck AJ; Chamie K
Urol Oncol; 2018 Feb; 36(2):79.e19-79.e26. PubMed ID: 29103965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
